Efficacy of 1st line eradication therapy in the groups
Groups
Number of patients with effective anti-Helicobacter therapy
Number of patients receiving anti-Helicobacter therapy in groups
%
1
36
43
83.7
2
29
42
69.1
3
39
42
92.9
4
33
41
80.5
Declarations
Author contributions
LGB, IVM, DTD, and VIR have equally contributed to Conceptualization, Formal Analysis, Writing—original draft, Writing—review & editing. All authors read and approved the final version.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Ethical approval
The study “The significance of chronic hyperglycemia for the reduced efficacy of eradication therapy in patients with type 2 diabetes mellitus and for Helicobacter pylori survival” was approved by the Interuniversity Ethics Committee.
Consent to participate
The informed consent to participate in the study was obtained from all participants.
Dedov II, Shestakova MV, Aleksandrov AA, Galstyan GR, Grigoryan OR, Esayan RM, et al. Algorithms of specialized medical care for diabetes mellitus patients.Diabetes mellitus. 2011;14:2–72. Russian.
Mkrtumyan A, Kazyulin AN, Bairova KI. Incidence and graveness of helicobacter infection in patients with type 2 diabetes mellitus.Diabetes mellitus. 2010;13:77–9. Russian.
Younus HA, Alkabeer AM, Nuser MM, Mohammed A, Saleh M. Study of the relation between glycemic control in Egyptian patients with type-2 diabetes mellitus and Helicobacter pylori infection.Int J Multidiscip Res Dev. 2018;5:249–56.
Bener A, Ağan AF, Al-Hamaq AOAA, Barisik CC, Öztürk M, Ömer A. Prevalence of Helicobacter pylori infection among type 2 diabetes mellitus.Adv Biomed Res. 2020;9:27. [DOI] [PubMed] [PMC]
Li JZ, Li JY, Wu TF, Xu JH, Huang CZ, Cheng D, et al. Helicobacter pylori infection is associated with type 2 diabetes, not type 1 diabetes: an updated meta-analysis.Gastroenterol Res Pract. 2017;2017:5715403. [DOI] [PubMed] [PMC]
Mansori K, Dehghanbanadaki H, Naderpour S, Rashti R, Moghaddam AB, Moradi Y. A systematic review and meta-analysis of the prevalence of Helicobacter pylori in patients with diabetes.Diabetes Metab Syndr. 2020;14:601–7. [DOI] [PubMed]
Mansori K, Moradi Y, Naderpour S, Rashti R, Moghaddam AB, Saed L, et al. Helicobacter pylori infection as a risk factor for diabetes: a meta-analysis of case-control studies.BMC Gastroenterol. 2020;20:77. [DOI] [PubMed] [PMC]
Kouitcheu Mabeku LB, Noundjeu Ngamga ML, Leundji H. Helicobacter pylori infection, a risk factor for type 2 diabetes mellitus: a hospital-based cross-sectional study among dyspeptic patients in Douala-Cameroon.Sci Rep. 2020;10:12141. [DOI] [PubMed] [PMC]
Zhou J, Wang X, Liu K, Chen K. Association between Helicobacter pylori infection and the risk of type 2 diabetes mellitus based on a middle-aged and elderly Chinese population.Endocr J. 2022;69:839–46. [PubMed]
Maev IV, Mkrtumyan AM, Bektemirova LG, Andreev DN, Dicheva DT. The effectiveness of eradication therapy of the 1st line of Helicobacter pylori infection in patients with type 2 diabetes mellitus.Ter Arkh. 2022;94:209–15. Russian. [PubMed]
Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, et al. European registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients.Gut. 2021;70:40–54. [DOI] [PubMed]
Reshetnyak V, Maev IV. Maintaining the metabolic homeostasis of Helicobacter pylori through chronic hyperglycemia in diabetes mellitus: a hypothesis.World J Meta-Anal. 2022;10:238–43. [DOI]
Gasbarrini A, Ojetti V, Pitocco D, Armuzzi A, Silveri NG, Pola P, et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus.Scand J Gastroenterol. 2000;35:260–3. [DOI] [PubMed]
Andreev DN, Maev IV, Kucheryavyy YA, Dicheva DT. Assessment of related anamnestic and clinical factors on efficacy and safety of anti-helicobacter pylori therapy.Russ Arch Int Med. 2016;6:29–33. [DOI]
Horikawa C, Kodama S, Fujihara K, Hirasawa R, Yachi Y, Suzuki A, et al. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis.Diabetes Res Clin Pract. 2014;106:81–7. [DOI] [PubMed]
Petri A, Sabin K. Visual medical statistics. Tutorial. 3rd ed. VP Leonov, editor. Moscow: GEOTAR-Media; 2019. Russian.
Mezmale L, Coelho LG, Bordin D, Leja M. Review: epidemiology of Helicobacter pylori.Helicobacter. 2020;25:e12734. [DOI] [PubMed]
Reshetnyak VI, Burmistrov AI, Maev IV. Helicobacter pylori: commensal, symbiont or pathogen?World J Gastroenterol. 2021;27:545–60. [DOI] [PubMed] [PMC]
Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report.Gut. 2022;[Epub ahead of print]. [DOI] [PubMed]
Sahoo OS, Mitra R, Bhattacharjee A, Kar S, Mukherjee O. Is diabetes mellitus a predisposing factor for Helicobacter pylori infections?Curr Diab Rep. 2023;23:195–205. [DOI] [PubMed]
Reshetnyak V, Burmistrov AI. On the 40th anniversary of the discovery of Helicobacter pylori.Health care Tajikistan. 2022;2:120–33. Russian. [DOI]
Ivashkin V, Mayev IV, Lapina TL, Sheptulin AA, Trukhmanov A, Baranskaya Y, et al. Diagnostics and treatment of Helicobacter pylori infection in adults: clinical guidelines of the Russian gastroenterological association.Russ J Gastroenterol Hepatol Coloproctology. 2018;28:55–70. Russian. [DOI]
Chen Y, Blaser MJ. Association between gastric Helicobacter pylori colonization and glycated hemoglobin levels.J Infect Dis. 2012;205:1195–202. [DOI] [PubMed] [PMC]
Sheu SM, Cheng H, Kao CY, Yang YJ, Wu JJ, Sheu BS. Higher glucose level can enhance the H. pylori adhesion and virulence related with type IV secretion system in AGS cells.J Biomed Sci. 2014;21:96. [DOI] [PubMed] [PMC]
Chávez-Reyes J, Escárcega-González CE, Chavira-Suárez E, León-Buitimea A, Vázquez-León P, Morones-Ramírez JR, et al. Susceptibility for some infectious diseases in patients with diabetes: the key role of glycemia.Front Public Health. 2021;9:559595. [DOI] [PubMed] [PMC]
Mendz GL, Hazell SL. Aminoacid utilization by Helicobacter pylori.Int J Biochem Cell Biol. 1995;27:1085–93. [DOI] [PubMed]
Kelly DJ. The physiology and metabolism of the human gastric pathogen Helicobacter pylori.Adv Microb Physiol. 1998;40:137–89. [DOI] [PubMed]
Mendz GL, Hazell SL, Burns BP. Glucose utilization and lactate production by Helicobacter pylori.J Gen Microbiol. 1993;139:3023–8. [DOI] [PubMed]
Som S, De A, Banik GD, Maity A, Ghosh C, Pal M, et al. Mechanisms linking metabolism of Helicobacter pylori to 18O and 13C-isotopes of human breath CO2.Sci Rep. 2015;5:10936. [DOI] [PubMed] [PMC]
Ho CY, Liu TW, Lin YS, Chen YP, Chen MJ, Wang HY, et al. Factors affecting the intraluminal therapy for Helicobacter pylori infection.Microorganisms. 2022;10:415. [DOI] [PubMed] [PMC]
Wang YC, Chen YP, Ho CY, Liu TW, Chu CH, Wang HY, et al. The impact of gastric juice pH on the intraluminal therapy for Helicobacter pylori infection.J Clin Med. 2020;9:1852. [DOI] [PubMed] [PMC]
Reshetnyak VI, Reshetnyak TM. Significance of dormant forms of Helicobacter pylori in ulcerogenesis.World J Gastroenterol. 2017;23:4867–78. [DOI] [PubMed] [PMC]
Chen J, Xing Y, Zhao L, Ma H. The association between Helicobacter pylori infection and glycated hemoglobin A in diabetes: a meta-analysis.J Diabetes Res. 2019;2019:3705264. [DOI] [PubMed] [PMC]
Mbanya JC, Henry RR, Smith U. Presidents’ statement on WHO recommendation on HbA1c for diabetes diagnosis.Diabetes Res Clin Pract. 2011;93:310–1. [DOI] [PubMed]
Buell C, Kermah D, Davidson MB. Utility of A1C for diabetes screening in the 1999 2004 NHANES population.Diabetes Care. 2007;30:2233–5. [DOI] [PubMed]
Tseng CH. Diabetes, insulin use and Helicobacter pylori eradication: a retrospective cohort study.BMC Gastroenterol. 2012;12:46. [DOI] [PubMed] [PMC]
Howard BV, Best L, Comuzzie A, Ebbesson SO, Epstein SE, Fabsitz RR, et al. C-reactive protein, insulin resistance, and metabolic syndrome in a population with a high burden of subclinical infection: insights from the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study.Diabetes Care. 2008;31:2312–4. [DOI] [PubMed] [PMC]
Lutsey PL, Pankow JS, Bertoni AG, Szklo M, Folsom AR. Serological evidence of infections and type 2 diabetes: the MultiEthnic Study of Atherosclerosis.Diabet Med. 2009;26:149–52. [DOI] [PubMed] [PMC]
Zibaei M, Bahadory S, Saadati H, Pourrostami K, Firoozeh F, Foroutan M. Intestinal parasites and diabetes: a systematic review and meta-analysis.New Microbes New Infect. 2022;51:101065. [DOI] [PubMed] [PMC]
